[Rich66]

Studies to watch:

http://clinicaltrials.gov/ct/show/NCT00301106?order=1

Biological Therapy in Treating Women With Breast Cancer That Has Spread to the Liver
This study is ongoing, but not recruiting participants.
First Received: March 8, 2006 Last Updated: February 27, 2009 History of Changes
Sponsored by: Mount Sinai School of Medicine
Information provided by: National Cancer Institute (NCI) ClinicalTrials.gov Identifier: NCT00301106

Purpose RATIONALE: Biological therapy using a gene-modified virus that can make interleukin-12 may help the body build an effective immune response to kill tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of a gene-modified virus that can make interleukin-12 in treating women with breast cancer that has spread to the liver.


Condition Intervention Phase Breast Cancer
Metastatic Cancer
Biological: adenovirus-mediated human interleukin-12
Phase I

http://clinicaltrials.gov/ct2/show/NCT00004893

Interleukin-12 in Treating Patients With Metastatic or Recurrent Breast Cancer

This study is ongoing, but not recruiting participants.

First Received: March 7, 2000 Last Updated: February 6, 2009 History of Changes

Sponsors and Collaborators:

Cancer and Leukemia Group B
National Cancer Institute (NCI)

Information provided by:

National Cancer Institute (NCI)

ClinicalTrials.gov Identifier:

NCT00004893

Purpose
RATIONALE: Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill breast cancer cells.
PURPOSE: Randomized phase II trial to study the effectiveness of interleukin-12 in treating patients who have metastatic or recurrent breast cancer.

Condition

Intervention

Phase

Breast Cancer
Biological: recombinant interleukin-12
Phase II

Show 49 Study Locations